B

BioLineRx Ltd
D

BLRX

3.63000
USD
-0.22
(-5.71%)
مغلق
حجم التداول
928
الربح لكل سهم
-10
العائد الربحي
-
P/E
-0
حجم السوق
12,917,366
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ADVM
    -0.03500
    (-0.88%)
    3.95000 USD
    A
    ARDX
    -0.65000
    (-11.39%)
    5.05500 USD
    B
    BPMC
    -2.080
    (-2.20%)
    92.280 USD
    I
    INVA
    -0.040
    (-0.22%)
    18.050 USD
    R
    RDHL
    -0.08000
    (-1.64%)
    4.81000 USD
    T
    TNXP
    -0.53000
    (-5.48%)
    9.15000 USD
    المزيد
الأخبار
المقالات

العنوان: BioLineRx Ltd

القطاع: Healthcare
الصناعة: Biotechnology
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.